Stay on the Cutting Edge of Biotech, MedTech, and Pharma

Discover healthcare innovations with expert insights, in-depth articles, and cutting-edge research. Stay informed with BioMed Nexus.

Recent Posts:

Biotech

20 Biotech Startups to Watch in 2025

Biotechnology is advancing rapidly, driving innovation across healthcare, agriculture, food, and manufacturing. At the forefront of these advancements are gene editing technologies like CRISPR/Cas9, which enable precise modifications to the genetic code of living organisms. This technology holds promise for treating genetic disorders and enhancing agricultural productivity. Meanwhile, synthetic biology is enabling the design of new biological systems and molecules, facilitating developments in pharmaceuticals, biofuels,

Read More »
Daily Updates

Biotech M&A Boom: $8B Genmab Deal & Major FDA Approvals – Oct 2025

Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion Oncology Bet: The EGFR×LGR5 Bispecific Gamble Danish biotechnology giant Genmab announced it will acquire Netherlands-based Merus for approximately $8 billion

Read More »

Be the first to know about new posts

Biotech

Daily Updates

Biotech M&A Boom: $8B Genmab Deal & Major FDA Approvals – Oct 2025

Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion Oncology Bet: The EGFR×LGR5 Bispecific Gamble Danish biotechnology giant Genmab announced it will acquire Netherlands-based Merus for approximately $8 billion

Read More »

Medtech

Daily Updates

Biotech M&A Boom: $8B Genmab Deal & Major FDA Approvals – Oct 2025

Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion Oncology Bet: The EGFR×LGR5 Bispecific Gamble Danish biotechnology giant Genmab announced it will acquire Netherlands-based Merus for approximately $8 billion

Read More »

Pharma

Daily Updates

Biotech M&A Boom: $8B Genmab Deal & Major FDA Approvals – Oct 2025

Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion Oncology Bet: The EGFR×LGR5 Bispecific Gamble Danish biotechnology giant Genmab announced it will acquire Netherlands-based Merus for approximately $8 billion

Read More »

#BioMedNexus

Join a Community of 35,000+ Industry Leaders and Innovators

Stay Ahead in Biotech & MedTech Innovations

Join the BioMed Nexus community and get the latest breakthroughs, research updates, and industry insights delivered straight to your inbox.